Clopidogrel monotherapy is noninferior to extended dual antiplatelet therapy (DAPT) for adverse clinical events in high-risk patients who complete 12 months of DAPT after drug-eluting stent (DES) implantation, according to late-breaking data from the A-CLOSE trial.